Generic GlucaGen Availability
GlucaGen is a brand name of glucagon, approved by the FDA in the following formulation(s):
GLUCAGEN (glucagon hydrochloride recombinant - injectable; injection)
-
Manufacturer: NOVO NORDISK
Approval date: June 22, 1998
Strength(s): EQ 1MG BASE/VIAL [RLD]
Has a generic version of GlucaGen been approved?
No. There is currently no therapeutically equivalent version of GlucaGen available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of GlucaGen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with GlucaGen.
See also...
- GlucaGen Consumer Information (Wolters Kluwer)
- GlucaGen Consumer Information (Cerner Multum)
- Glucagen Advanced Consumer Information (Micromedex)
- Glucagen Diagnostic Kit Advanced Consumer Information (Micromedex)
- GlucaGen AHFS DI Monographs (ASHP)
- Glucagon Consumer Information (Wolters Kluwer)
- Glucagon Emergency Kit for Low Blood Sugar Consumer Information (Cerner Multum)
- Glucagon Consumer Information (Cerner Multum)
- Glucagon Diagnostic Kit Advanced Consumer Information (Micromedex)
- Glucagon Emergency Kit Advanced Consumer Information (Micromedex)
- Glucagon Injection Advanced Consumer Information (Micromedex)
- Glucagon AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
